Russell Investments Group
TRVI icon

Russell Investments Group’s Trevi Therapeutics TRVI Stock Holding History

Russell Investments Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.7M Buy
90,926
+22,806
+33% +$332K ﹤0.01% 2175
2026
Q1 		$813K Buy
68,120
+8,676
+15% +$97.1K ﹤0.01% 2312
2025
Q4 		$744K Buy
59,444
+2,984
+5% +$34.5K ﹤0.01% 2348
2025
Q3 		$517K Buy
56,460
+51,924
+1,145% +$389K ﹤0.01% 2464
2025
Q2 		$24.8K Buy
4,536
+2,996
+195% +$18.6K ﹤0.01% 3143
2025
Q1 		$9.69K Buy
+1,540
New +$7.35K ﹤0.01% 3243

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Russell Investments Group's TRVI Position: Q2 2026 in Review

Russell Investments Group increased its Trevi Therapeutics (TRVI) stake by 33% in Q2 2026, buying an estimated $332K and bringing the position to 90,926 shares worth $1.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Russell Investments Group first reported a position in TRVI in Q1 2025 and has held it in 6 quarters since. 86 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Russell Investments Group held 90,926 shares of Trevi Therapeutics worth $1.7M as of Q2 2026.
  • Russell Investments Group bought 22,806 Trevi Therapeutics shares in Q2 2026, an estimated $332K.
  • Trevi Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2175 holding.
  • Russell Investments Group first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 86 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.